Navigation Links
Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
Date:12/7/2007

generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 30 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase III clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.

Medarex Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product development, unforeseen safety issues resulting from the administration of antibody products in humans, uncertainties concerning Centocor's activities under its agreement with Medarex, as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and its quarterly reports on Form 10-Q. There can be no assurance that future milestone payments will be paid, whether the product develo
'/>"/>

SOURCE Medarex, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
2. Medarex to Present at the JPMorgan Small/Mid Cap Conference
3. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
4. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
5. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
6. DaVita Receives Civil Complaint
7. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
8. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
9. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
10. Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute
11. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... (PRWEB) December 26, 2014 Recently, iFitDress.com, the ... for women, has announced its new selection of black ... are on sale now; they are available at discounted prices, ... says, “The promotion will last for three weeks only. You ... market. Those who are interested in our new items can ...
(Date:12/25/2014)... 25, 2014 BambooFlooringChina.com sells many bamboo ... bamboo flooring. Today, the company announces big discounts ... styles and colors. , BambooFlooringChina.com is the world’s leader ... promotion is valid until Jan. 20, 2015. , The ... woven with a natural thread. All the bamboo strips ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... chronic illnesses can receive effective, less expensive care from a ... to a team of dedicated health care professionals, a new ... ill and need either hospitalization or a trip to the ... home clinic at the University of Texas in Houston versus ...
(Date:12/25/2014)... By Dennis Thompson ... -- Researchers could be closing in on a "fountain of ... improve the health of older adults, a new study suggests. ... when given a drug that targets a genetic signaling pathway ... maker Novartis report. The experimental medication, a ...
(Date:12/25/2014)... Plugin creators from Pixel Film Studios ... customizable business presentation tool made specifically for Final ... business tool, users can now display their stats and ... Film Studios. “ProFire 5k gives users a multiple options ... to a presentation” , Pixel Film Studios takes the ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... cancers that respond best to tyrosine kinase inhibitors (TKIs), ... according to research presented at the 14th World Conference ... Association for the Study of Lung Cancer (IASLC). ... for non-small cell lung cancer therapy, selecting the best ...
... common type of liver cancer, is a leading cause ... options available, they are largely unsuccessful because the disease ... HCC, combined with studies using mice and other animal ... how to diagnose and treat this deadly form of ...
... therapy helps ease chronic low back pain and improve function, ... of Internal Medicine will publish in its July 5 ... massage, the trial found that both types of massage worked ... helps people with back pain to function even after six ...
... are two to three times more likely to develop a life-threatening ... study published on bmj.com today. The new ... your risk of developing a pulmonary embolism a common cause ... says that, although the risk is small equivalent to seven ...
... Recent studies have revealed potato chips and french fries to ... good reason. Have you ever wondered why you can,t eat ... the carbohydrates at fault. UC Irvine researchers Daniele Piomelli, ... make them nearly irresistible and trigger a surprising biological mechanism ...
... smoking is associated with a 72% increased risk of ... CMAJ ( Canadian Medical Association Journal ) (pre-embargo link ... cause of serious illness and death in smokers and ... Varenicline is one of the most commonly used drugs ...
Cached Medicine News:Health News:PET scan with [11C]erlotinib may provide noninvasive method to identify TKI-responsive lung tumors 2Health News:Research in fish provides new clues about deadly form of liver cancer 2Health News:Massage eases low back pain in randomized controlled trial 2Health News:Massage eases low back pain in randomized controlled trial 3Health News:Sitting for long periods doubles risk of blood clots in the lungs 2Health News:Body's natural marijuana-like chemicals make fatty foods hard to resist 2Health News:Varenicline for smoking cessation linked to increased risk of serious harmful cardiac events 2
(Date:12/24/2014)... TIJUANA, Mexico , Dec. 24, 2014 /PRNewswire/ ... treatment of its first patient in its study ... to the American Stroke Association, ischemic strokes account ... continues to enroll qualified patients in the study, ... Intravenous Administration of Allogeneic Mesenchymal Stem Cells and ...
(Date:12/24/2014)... -- Commonwealth Cornerstone Group (CCG) today announced the completion of an ... help fund the expansion and consolidation of healthcare services provided ... . PHN is the largest federally qualified ... is the largest employer in Sharon,s ... Currently, PHN Sharon offers scattered services out of ...
(Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals ... with KX2-361 at Roswell Park Cancer Institute. ... molecule drug that has shown potent inhibitory activity against ... those that are resistant to Temozolomide (T98G), the most ... In a well-established brain tumor mouse model, KX2-361 consistently ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3
Bard Coude-Tip Latex Urethral Catheter, Two Eyes (Tiemann Model)...
Red Latex Bardex I.C. Foley 2-Way Catheter (Council Model)...
The BARDEX I.C. Catheter represents Bard's newest technology in providing protection against NUTI....
Used for injection into urethral strictures, bladder neck contracture, and the bladder wall. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: